20 results on '"Karhadkar S"'
Search Results
2. Waitlist Outcomes for Exception and Non-exception Liver Transplant Candidates in the United States Following Implementation of the Median MELD at Transplant (MMaT)/250-mile Policy.
- Author
-
Ishaque T, Beckett J, Gentry S, Garonzik-Wang J, Karhadkar S, Lonze BE, Halazun KJ, Segev D, and Massie AB
- Subjects
- Humans, Male, Female, Middle Aged, United States epidemiology, Adult, Time Factors, Aged, Risk Factors, Tissue and Organ Procurement, Risk Assessment, Patient Selection, Treatment Outcome, Liver Transplantation adverse effects, Liver Transplantation mortality, Waiting Lists mortality, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular mortality, Liver Neoplasms surgery, Liver Neoplasms mortality, Registries, End Stage Liver Disease surgery, End Stage Liver Disease mortality, End Stage Liver Disease diagnosis
- Abstract
Background: Since February 2020, exception points have been allocated equivalent to the median model for end-stage liver disease at transplant within 250 nautical miles of the transplant center (MMaT/250). We compared transplant rate and waitlist mortality for hepatocellular carcinoma (HCC) exception, non-HCC exception, and non-exception candidates to determine whether MMaT/250 advantages (or disadvantages) exception candidates., Methods: Using Scientific Registry of Transplant Recipients data, we identified 23 686 adult, first-time, active, deceased donor liver transplant (DDLT) candidates between February 4, 2020, and February 3, 2022. We compared DDLT rates using Cox regression, and waitlist mortality/dropout using competing risks regression in non-exception versus HCC versus non-HCC candidates., Results: Within 24 mo of study entry, 58.4% of non-exception candidates received DDLT, compared with 57.8% for HCC candidates and 70.5% for non-HCC candidates. After adjustment, HCC candidates had 27% lower DDLT rate (adjusted hazard ratio = 0.68 0.73 0.77 ) compared with non-exception candidates. However, waitlist mortality for HCC was comparable to non-exception candidates (adjusted subhazard ratio [asHR] = 0.93 1.03 1.15 ). Non-HCC candidates with pulmonary complications of cirrhosis or cholangiocarcinoma had substantially higher risk of waitlist mortality compared with non-exception candidates (asHR = 1.27 1.70 2.29 for pulmonary complications of cirrhosis, 1.35 2.04 3.07 for cholangiocarcinoma). The same was not true of non-HCC candidates with exceptions for other reasons (asHR = 0.54 0.88 1.44 )., Conclusions: Under MMaT/250, HCC, and non-exception candidates have comparable risks of dying before receiving liver transplant, despite lower transplant rates for HCC. However, non-HCC candidates with pulmonary complications of cirrhosis or cholangiocarcinoma have substantially higher risk of dying before receiving liver transplant; these candidates may merit increased allocation priority., Competing Interests: This work was supported by grants R01DK132395 (A.B.M.) from the National Institute of Diabetes and Digestive and Kidney Diseases and K24AI144954 (D.S.) from the National Institute of Allergy and Infectious Diseases. The other authors declare no conflicts of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Unrecognized opportunities: The landscape of pediatric kidney-paired donation in the United States.
- Author
-
Verbesey J, Thomas AG, Waterman AD, Karhadkar S, Cassell VR, Segev DL, Hogan J, and Cooper M
- Subjects
- Humans, United States, Child, Adolescent, Living Donors, Tissue and Organ Harvesting, Histocompatibility, Kidney, Kidney Transplantation methods, Tissue and Organ Procurement
- Abstract
Background: Pediatric (age < 18 years) kidney transplant (KT) candidates face increasingly complex choices. The 2014 kidney allocation system nearly doubled wait times for pediatric recipients. Given longer wait times and new ways to optimize compatibility, more pediatric candidates may consider kidney-paired donation (KPD). Motivated by this shift and the potential impact of innovations in KPD practice, we studied pediatric KPD procedures in the US from 2008 to 2021., Methods: We describe the characteristics and outcomes of pediatric KPD recipients with comparison to pediatric non-KPD living donor kidney transplants (LDKT), pediatric LDKT recipients, and pediatric deceased donor (DDKT) recipients., Results: Our study cohort includes 4987 pediatric DDKTs, 3447 pediatric non-KPD LDKTs, and 258 pediatric KPD transplants. Fewer centers conducted at least one pediatric KPD procedure compared to those that conducted at least one pediatric LDKT or DDKT procedure (67, 136, and 155 centers, respectively). Five centers performed 31% of the pediatric KPD transplants. After adjustment, there were no differences in graft failure or mortality comparing KPD recipients to non-KPD LDKT, LDKT, or DDKT recipients., Discussion: We did not observe differences in transplant outcomes comparing pediatric KPD recipients to controls. Considering these results, KPD may be underutilized for pediatric recipients. Pediatric KT centers should consider including KPD in KT candidate education. Further research will be necessary to develop tools that could aid clinicians and families considering the time horizon for future KT procedures, candidate disease and histocompatibility characteristics, and other factors including logistics and donor protections., (© 2023 The Authors. Pediatric Transplantation published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
4. Longevity Matching for Living Donor Renal Transplantation.
- Author
-
Dawes J, Gregor A, Kolansky J, Wirshup K, Di Carlo A, and Karhadkar S
- Subjects
- Humans, Living Donors, Regression Analysis, Graft Survival, Kidney, Kidney Transplantation adverse effects, Tissue and Organ Procurement
- Abstract
Introduction: This study identifies the effect of individual donor and recipient characteristics on graft survival in living-donor kidney transplantation (LDKT) using a recently described novel measure, kidney life years (KLYs)., Materials and Methods: The Organ Procurement and Transplantation Network/United Network for Organ Sharing database was used to identify first-time kidney-only LDKT recipients between 1987 and 2020 who did not experience death with a functioning graft (DWFG) and were not missing relevant information (n = 87,290). Patient characteristics were evaluated using Cox and multiple regression analyses, with the dependent variable being KLYs. An equation for expected KLYs based on patient characteristics was created using regression coefficients. The equation was validated using bootstrapped Pearson correlations and then applied to the DWFG group for comparison., Results: Based on statistical significance from Cox and multiple linear regression analyses, 9 of the original 18 variables were selected for inclusion in the equation. Variables with notable impact included HLA match points (0.021 KLYs; 95% CI: [0.019,0.024]; P ≤ .001), Donor Age (-0.030 KLYs; 95% CI: [-0.035,-0.025]; P ≤ .001), and Donor African American Ethnicity (-2.356 KLYs; 95% CI: [-2.552,-2.159]; P ≤ .001). Equation validation was supported, given a negative correlation (r = -0.071; P ≤ .001) between expected KLY change and observed graft failure. Expected KLY change was found to be greater in those who eventually DWFG when compared with all other LDKTs (t = -5.735, P ≤ .001)., Conclusions: Increasing HLA match points may be more beneficial for graft longevity than minimizing donor age in comparisons using realistic between-donor differences. Additionally, greater average expected KLYs in those who ultimately DWFG may illustrate an opportunity for improved donor-recipient matching., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. Renal Cell Carcinoma in End-Stage Kidney Disease and the Role of Transplantation.
- Author
-
Robinson S, Nag A, Peticca B, Prudencio T, Di Carlo A, and Karhadkar S
- Abstract
Kidney transplant patients have a higher risk of renal cell carcinoma (RCC) compared to non-transplanted end-stage kidney disease (ESKD) patients. This increased risk has largely been associated with the use of immunosuppression; however, recent genetic research highlights the significance of tissue specificity in cancer driver genes. The implication of tissue specificity becomes more obscure when addressing transplant patients, as two distinct metabolic environments are present within one individual. The oncogenic potential of donor renal tissue is largely unknown but assumed to pose minimal risk to the kidney transplant recipient (KTR). Our review challenges this notion by examining how donor and recipient microenvironments impact a transplant recipient's associated risk of renal cell carcinoma. In doing so, we attempt to encapsulate how ESKD-RCC and KTR-RCC differ in their incidence, pathogenesis, outcome, and approach to management.
- Published
- 2023
- Full Text
- View/download PDF
6. Dosing strategies for de novo once-daily extended release tacrolimus in kidney transplant recipients based on CYP3A5 genotype.
- Author
-
Diamond A, Karhadkar S, Chavin K, Constantinescu S, Lau KN, Perez-Leal O, Mohrien K, Sifontis N, and Di Carlo A
- Abstract
Background: Tacrolimus extended-release tablets have been Food and Drug Administration-approved for use in the de novo kidney transplant population. Dosing requi rements often vary for tacrolimus based on several factors including variation in metabolism based on CYP3A5 expression. Patients who express CYP3A5 often require higher dosing of immediate-release tacrolimus, but this has not been established for tacrolimus extended-release tablets in the de novo setting., Aim: To obtain target trough concentrations of extended-release tacrolimus in de novo kidney transplant recipients according to CYP3A5 genotype., Methods: Single-arm, prospective, single-center, open-label, observational study (ClinicalTrials.gov: NCT037 13645). Life cycle pharma tacrolimus (LCPT) orally once daily at a starting dose of 0.13 mg/kg/day based on actual body weight. If weight is more than 120% of ideal body weight, an adjusted body weight was used. LCPT dose was adjusted to maintain tacrolimus trough concentrations of 8-10 ng/mL. Pharmacogenetic analysis of CYP3A5 genotype was performed at study conclusion., Results: Mean time to therapeutic tacrolimus trough concentration was longer in CYP3A5 intermediate and extensive metabolizers vs CYP3A5 non-expressers (6 d vs 13.5 d vs 4.5 d; P = 0.025). Mean tacrolimus doses and weight-based doses to achieve therapeutic concentration were higher in CYP3A5 intermediate and extensive metabolizers vs CYP3A5 non-expressers (16 mg vs 16 mg vs 12 mg; P = 0.010) (0.20 mg/kg vs 0.19 mg/kg vs 0.13 mg/kg; P = 0.018). CYP3A5 extensive metabolizers experienced lower mean tacrolimus trough concentrations throughout the study period compared to CYP3A5 intermediate metabolizers and non-expressers (7.98 ng/mL vs 9.18 ng/mL vs 10.78 ng/mL; P = 0 0.008). No differences were identified with regards to kidney graft function at 30-d post-transplant. Serious adverse events were reported for 13 (36%) patients., Conclusion: Expression of CYP3A5 leads to higher starting doses and incremental dosage titration of extended-release tacro limus to achieve target trough concentrations. We suggest a higher starting dose of 0.2 mg/kg/d for CYP3A5 expressers., Competing Interests: Conflict-of-interest statement: Adam Diamond serves as an active member of the Veloxis Pharmaceuticals Speaker’s Bureau (honoraria provided)., (©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. Deciphering the True Immunologic Risk in Renal Transplantation in Patients With HIV.
- Author
-
Kahler D, Curtis H, Zhao H, Diamond A, Di Carlo A, and Karhadkar S
- Subjects
- Humans, Living Donors, Kidney, Transplantation, Homologous, Graft Survival, Graft Rejection, Kidney Transplantation adverse effects, HIV Infections complications
- Abstract
Since 1995, rates of end-stage renal disease have risen dramatically in patients living with HIV infection. However, given the concern for higher rates of acute rejection in this patient population, the immunologic threat posed by HIV infection is a specter clinicians must continually confront. Living donor transplantation may negate this risk; this study aims to assess the benefit of living donor transplantation in this population and to ascertain the immunologic risk faced by patients who are HIV-infected. The 2021 UNOS database was queried, and all HIV-infected kidney transplant recipients since 1987 were identified. Recipients were stratified based on deceased (DDKT) vs living (LDKT) donor status. Overall survival, allograft survival, acute rejection, panel reactive antibody (PRA) percentage, and crossmatch positivity were compared between groups. One thousand two hundred twenty-six patients underwent DDKT, and 304 patients underwent LDKT. Living donor kidney transplantation demonstrated greater overall survival (P = .045) and graft survival (P < .001). However, no difference in acute rejection was noted between the cohorts, and no difference in overall or graft survival was evident based on PRA percentage. Crossmatch positive status did not negatively affect graft survival. Patients with HIV undergoing LDKT fared better than those undergoing DDKT. Nevertheless, patients at higher immunologic risk-elevated PRA% and crossmatch positivity-did not experience graft loss at a higher rate than patients at lower immunologic risk. These results were valid in both DDKT and LDKT cohorts. These findings suggest that infection with HIV does not overtly increase patients' immunologic risk, and concerns surrounding transplantation in this population may be overestimated., Competing Interests: Declaration of Competing Interest All the authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
8. Benefit of Kidney Transplantation for Post Lung Transplantation Renal Failure.
- Author
-
Gregor A, Kolansky J, Wirshup K, Dawes J, Zhao H, Di Carlo A, and Karhadkar S
- Subjects
- Humans, Transplantation, Homologous, Graft Survival, Kidney Transplantation adverse effects, Lung Transplantation, Tissue and Organ Procurement, Kidney Failure, Chronic surgery
- Abstract
Introduction: Nephrotoxicity is a significant side effect of thoracic transplantation. Many lung transplant patients will require subsequent renal transplantation (KAL). Recently, simultaneous lung/kidney transplants (SLuK) have become an attractive option for patients with end-stage renal disease at the time of lung transplantation. This article explores SLuK outcomes compared to conventional KAL, as well as outcomes among KAL patients against those were KAL listed but never transplanted., Materials and Methods: The United Network for Organ Sharing/the Organ Procurement and Transportation Network database was used to identify SLuK patients (n = 74), KAL transplants (n = 456), and patients who were listed for KAL but were never transplanted (n = 626). Significance was determined by chi
2 , Wilcoxon rank sum test, or independent t-tests. Death-censored graft survival for subgroups was estimated using Kaplan-Meier with log-rank for significance. Analyses were completed using SPSS Statistics 28., Results: The SLuK cohort was older (P = 0.04), more likely diabetic (P < 0.001), and had shorter life expectancies (P < 0.001) than KAL patients. Of those SLuK transplants within 5 y, 84% of patients were alive 1 y post transplant and 82% were alive 3 y post-transplant (compared to 74.6% and 60.3% of overall SLuK). Patients who did undergo KAL were younger and had a lower body mass index (both P < 0.001) compared to those who did not. Those who received a kidney had increased survival times compared to WL patients (P < 0.001)., Conclusions: Conventional KAL transplants are still favorable for average lung recipients. However, recent improvements have made SLuK an option for patients with renal dysfunction. Those patients who were able to receive KAL transplants were better surgical candidates than those who remained on the waitlist., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
9. Myocardial GRK2 Reduces Fatty Acid Metabolism and β-Adrenergic Receptor-Mediated Mitochondrial Responses.
- Author
-
Zhai R, Varner EL, Rao A, Karhadkar S, Di Carlo A, Snyder NW, and Sato PY
- Subjects
- Animals, Fatty Acids metabolism, Humans, Isoproterenol pharmacology, Mice, Mitochondria metabolism, Myocytes, Cardiac metabolism, Palmitates metabolism, G-Protein-Coupled Receptor Kinase 2 metabolism, Heart Failure metabolism, Receptors, Adrenergic, beta metabolism
- Abstract
G-protein coupled receptor (GPCR) kinase 2 (GRK2) is upregulated in heart failure (HF) patients and mouse models of cardiac disease. GRK2 is a regulator of β-adrenergic receptors (βARs), a GPCR involved in ionotropic and chronotropic responses. We and others have recently reported GRK2 to be localized in the mitochondria, although its function in the mitochondria and/or metabolism remain not clearly defined. We hypothesized that upregulation of GRK2 reduced mitochondrial respiratory function and responses to βAR activation. Utilizing isolated mouse primary adult cardiomyocytes (ACMs), we investigated the role of glucose, palmitate, ketone bodies, and BCAAs in mediating cell survival. Our results showed that myocyte upregulation of GRK2 promotes palmitate-induced cell death. Isotopologue labeling and mass spectrometry showed that the upregulation of GRK2 reduces β-hydroxybutyryl CoA generation. Next, using isoproterenol (ISO), a non-selective βAR-agonist, we determined mitochondrial function in mouse and human primary ACMs. Upregulation of GRK2 impaired ISO-mediated mitochondrial functional responses, which we propose is important for metabolic adaptations in pathological conditions. Increased cardiac levels of GRK2 reduced fatty acid-specific catabolic pathways and impaired ISO-stimulated mitochondrial function. Our data support the notion that GRK2 participates in bioenergetic remodeling and may be an important avenue for the development of novel pharmacological strategies in HF.
- Published
- 2022
- Full Text
- View/download PDF
10. Characterization of Kidney Retransplantation Following Graft Failure Due to BK Virus Nephropathy.
- Author
-
Nguyen K, Diamond A, Carlo AD, and Karhadkar S
- Subjects
- Graft Rejection epidemiology, Graft Rejection etiology, Graft Rejection prevention & control, Humans, Kidney, Reoperation, BK Virus physiology, Kidney Diseases, Polyomavirus Infections complications, Polyomavirus Infections epidemiology, Tumor Virus Infections complications, Tumor Virus Infections epidemiology
- Abstract
Introduction: Immunosuppression following kidney transplantation increases risk of BK polyomavirus reactivation, a common cause of graft dysfunction and failure. Subsequent retransplantation is a viable option that has not been extensively studied. This study further characterizes BK Virus Nephropathy (BKVN) and retransplantation in the most expansive population to date, geographically, temporally, and in magnitude., Materials and Methods: The OPTN/UNOS database was used to identify patients who received kidney or kidney-pancreas transplantation between 1987 and 2018 that resulted in BKVN-attributed failure (n = 1587). This population was divided into those who underwent retransplantation (n = 495) and those who did not (n = 1092)., Results: The retransplanted cohort was younger (45 vs. 53 yr; P<0.0001) and had fewer prior kidney transplants (P<0.003), lower expected post-transplant survival (P<0.001), lower rates of delayed graft function (DGF) (14.1% vs. 22.2%; P=0.0008), a greater proportion of white patients (55.4% vs. 43.2%; P=0.0002), a greater proportion of living donors (35.8% vs. 23.0%; P<0.0001), and longer allograft lifespan (2.95 vs. 2.41 yr; P<0.0001), compared to those not retransplanted. Among retransplants, DGF and high kidney donor profile index (KDPI) were associated with decreased allograft lifespan (P=0.001, P=0.0005, respectively). Steroid induction had no effect on allograft lifespan when compared to steroid-free regimens (P=0.915). Retransplanted allografts lasted longer than previous BKVN-failed grafts (10.44 and 3.70 years, respectively; P<0.0001)., Conclusions: Retransplantation following BKVN-associated graft failure has been associated with favorable outcomes. To maximize allograft lifespan in retransplantation, clinicians may consider selection of low KDPI donors, prevention of delayed graft function, and tailored immunosuppressive regimens that minimize steroids., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
11. High and Low Frequency Domino Liver Transplantation Centers Demonstrate Similar Performance Outcomes.
- Author
-
Panichella J, Curtis H, Nguyen K, Resweber C, Gunder M, Di Carlo A, and Karhadkar S
- Subjects
- Graft Survival, Humans, Retrospective Studies, Waiting Lists, Liver Transplantation, Living Donors
- Abstract
Introduction: A Domino Liver Transplant (DLT) is a successfully validated surgical option for a subset of patients awaiting liver transplant. Increased utilization of DLTs could increase the donor organ pool. However, DLTs occur primarily at a small number of high volume centers, and are rarely performed at lower volume transplant centers. This study compares DLT recipient performance outcomes between high frequency DLT centers and low frequency DLT centers., Methods: The UNOS/OPTN STAR database was queried for DLTs performed at transplant centers between 1996-2018. 193 patients were identified and categorized into high (>5 DLTs) or low (≤5 DLTs) frequency centers. Our primary endpoint was allograft survival. Our secondary endpoints were graft status at last follow up and mortality secondary to cardiac, renal, or respiratory failure., Results: Overall median allograft survival between high and low volume DLT centers was similar (48.2 months versus 42.7 months, P >0.314). The one-year (82% versus 76%), three-year (57% versus 56%), and five-year (45% versus 43%) survival percentages were also similar between the high and low volume DLT centers respectively. Overall mortality from cardiac (high 4% versus low 1.7%), renal (high 0.8% versus low 1.7%), or respiratory failure (high 0.8% versus low 1.7%) was similarly low in both groups., Conclusion: Low volume and high volume DLT centers are associated with similar outcomes of allograft survival and mortality. DLTs should be utilized more frequently, when the criteria are met, including in centers with limited experience, to expand the donor pool, decrease time on the waitlist, and improve overall survival., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
12. Enhancement of angiogenin inhibition by polyphenol-capped gold nanoparticles.
- Author
-
Panda A, Karhadkar S, Acharya B, Banerjee A, De S, and Dasgupta S
- Subjects
- Binding Sites, Binding, Competitive, Catechin analogs & derivatives, Catechin chemistry, Enzymes chemistry, Humans, Kinetics, Molecular Docking Simulation, Recombinant Proteins biosynthesis, Recombinant Proteins chemistry, Ribonuclease, Pancreatic antagonists & inhibitors, Ribonuclease, Pancreatic genetics, Spectrometry, Fluorescence, Enzymes metabolism, Gold chemistry, Metal Nanoparticles chemistry, Polyphenols chemistry, Ribonuclease, Pancreatic metabolism
- Abstract
Angiogenin (Ang), is a ribonucleolytic protein that is associated with angiogenesis, the formation of blood vessels. The involvement of Ang in vascularisation makes it a potential target for the identification of compounds that have the potential to inhibit the process. The compounds may be assessed for their ability to inhibit the ribonucleolytic activity of the protein and subsequently blood vessel formation, a crucial requirement for tumor formation. We report an inhibition of the ribonucleolytic activity of Ang with the gallate containing green tea polyphenols, ECG and EGCG that exhibits an increased efficacy upon forming polyphenol-capped gold nanoparticles (ECG-AuNPs and EGCG-AuNPs). The extent of inhibition was confirmed using an agarose gel-based assay followed by fluorescence titration studies that indicated a hundred fold stronger binding of polyphenol-capped gold nanoparticles (GTP-AuNPs) compared to the bare polyphenols. Interestingly, we found a change in the mode of inhibition from a noncompetitive type to a competitive mode of inhibition in case of the GTP-AuNPs, which is in agreement with the 'n' values obtained from the fluorescence quenching studies. The effect on angiogenesis has also been assessed by the chorioallantoic membrane (CAM) assay. We find an increase in the inhibition potency of GTP-AuNPs that could find applications in the development of anti-angiogenic compounds., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
13. Frailty Predicts Morbidity and Mortality After Laparoscopic Cholecystectomy for Acute Cholecystitis: An ACS-NSQIP Cohort Analysis.
- Author
-
Fagenson AM, Powers BD, Zorbas KA, Karhadkar S, Karachristos A, Di Carlo A, and Lau KN
- Subjects
- Cohort Studies, Humans, Morbidity, Postoperative Complications epidemiology, Postoperative Complications etiology, Quality Improvement, Retrospective Studies, Cholecystectomy, Laparoscopic adverse effects, Cholecystitis, Acute surgery, Frailty complications
- Abstract
Background: Current guidelines recommend laparoscopic cholecystectomy be offered for patients with acute cholecystitis except those deemed as high risk. Few studies have examined the impact of frailty on outcomes for patients undergoing laparoscopic cholecystectomy. Therefore, the aim of this study was to determine the association of frailty with postoperative morbidity and mortality in patients undergoing laparoscopic cholecystectomy for acute cholecystitis., Methods: Patients undergoing laparoscopic cholecystectomy for acute cholecystectomy were identified from 2005 to 2010 in the American College of Surgeons National Surgical Quality Improvement Project (NSQIP). The Modified Frailty Index (mFI) was used a surrogate for frailty, and patients were stratified as non-frail (mFI 0), low frailty (mFI 1-2), intermediate frailty (mFI 3-4) and high frailty (mFI ≥ 5). Univariable and multivariable analyses were performed. Receiver operator curves (ROC) and an area under the curve (AUC) were generated to determine accuracy of mFI in predicting postoperative morbidity and mortality., Results: Of the 6898 patients undergoing laparoscopic cholecystectomy, 3245 (47%) patients were non-frail. There were 2913 (42%) patients with low-frailty, 649 (9%) patients with intermediate frailty, and 91 (2%) with high frailty. Clavien IV complications were higher for intermediate frail patients (OR 1.81, 95% CI 1.00-3.28, p = 0.050) and high-frail patients (OR 4.59, 95% CI 1.98-10.7, p < 0.001). Additionally, mortality was higher for patients with intermediate frailty (OR 4.69, 95% CI 1.37-16.0, p = 0.014) and high frailty (OR 12.2, 95% CI 2.67-55.5, p = 0.001). The mFI had excellent accuracy for mortality (AUC = 0.83) and Clavien IV complications (AUC = 0.73)., Conclusion: Frailty is associated with postoperative morbidity and mortality in patients undergoing laparoscopic cholecystectomy for acute cholecystitis.
- Published
- 2021
- Full Text
- View/download PDF
14. Mitochondrial Membrane Intracellular Communication in Healthy and Diseased Myocardium.
- Author
-
Kumar VK, Lackey A, Snyder J, Karhadkar S, Rao AD, DiCarlo A, and Sato PY
- Abstract
Research efforts in the twenty-first century have been paramount to the discovery and development of novel pharmacological treatments in a variety of diseases resulting in improved life expectancy. Yet, cardiac disease remains a leading cause of morbidity and mortality worldwide. Over time, there has been an expansion in conditions such as atrial fibrillation (AF) and heart failure (HF). Although past research has elucidated specific pathways that participate in the development of distinct cardiac pathologies, the exact mechanisms of action leading to disease remain to be fully characterized. Protein turnover and cellular bioenergetics are integral components of cardiac diseases, highlighting the importance of mitochondria and endoplasmic reticulum (ER) in driving cellular homeostasis. More specifically, the interactions between mitochondria and ER are crucial to calcium signaling, apoptosis induction, autophagy, and lipid biosynthesis. Here, we summarize mitochondrial and ER functions and physical interactions in healthy physiological states. We then transition to perturbations that occur in response to pathophysiological challenges and how this alters mitochondrial-ER and other intracellular organelle interactions. Finally, we discuss lifestyle interventions and innovative therapeutic targets that may be used to restore beneficial mitochondrial and ER interactions, thereby improving cardiac function., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2020 Kumar, Lackey, Snyder, Karhadkar, Rao, DiCarlo and Sato.)
- Published
- 2020
- Full Text
- View/download PDF
15. Renal Cell Carcinoma in Kidney Transplant Candidates.
- Author
-
Zorbas KA, Karhadkar SS, Lau KN, and Di Carlo A
- Subjects
- Adult, Carcinoma, Renal Cell diagnostic imaging, Carcinoma, Renal Cell etiology, Female, Humans, Incidence, Kidney Failure, Chronic complications, Kidney Neoplasms diagnostic imaging, Kidney Neoplasms etiology, Male, Middle Aged, Nephrectomy methods, Preoperative Care, Renal Dialysis adverse effects, Retrospective Studies, Tomography, X-Ray Computed methods, Carcinoma, Renal Cell epidemiology, Kidney Failure, Chronic surgery, Kidney Neoplasms epidemiology, Kidney Transplantation statistics & numerical data
- Abstract
Background: An increased incidence of renal cell carcinoma (RCC) has been observed in patients with end-stage renal disease. However, the incidence of this pathological condition has not been studied adequately in kidney transplant candidates. The aim of this study was to examine the incidence of RCC and the clinical, imaging, and pathological characteristics in this population., Methods: At our institution, the majority of kidney transplant candidates undergo a non-contrast abdominal computerized tomography (CT) scan as a pre-transplant screening evaluation method. We retrospectively reviewed the medical data from 637 patients who were referred to our institution for kidney transplant evaluation during a period of 2 years. Of these, 174 were found ineligible and were excluded from the study; the final population consisted of 463 patients. Radical nephrectomy was proposed and performed in all the patients with findings highly suspicious of malignancy., Results: A total of 20 patients had findings suspicious for kidney malignancy on non-contrast CT scan and underwent a total nephrectomy before transplantation. At the pathological examination, 13 patients had malignant lesions and 4 patients had benign lesions. All patients with malignancy were male, and 9 of 13 patients with malignancy had papillary RCC., Conclusions: This study confirms the increased incidence of RCC in kidney transplant candidates and underlines the utility of non-contrast CT scan without an intravenous contrast agent as a very useful screening tool in the pre-operative evaluation of kidney transplant candidates. Hence, we recommend the implementation of routine screening with non-contrast CT scan in all kidney transplant candidates who undergo hemodialysis., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
16. Systemic Delivery of scAAV8-Encoded MiR-29a Ameliorates Hepatic Fibrosis in Carbon Tetrachloride-Treated Mice.
- Author
-
Knabel MK, Ramachandran K, Karhadkar S, Hwang HW, Creamer TJ, Chivukula RR, Sheikh F, Clark KR, Torbenson M, Montgomery RA, Cameron AM, Mendell JT, and Warren DS
- Subjects
- Animals, Carbon Tetrachloride, Cell Line, Chemical and Drug Induced Liver Injury genetics, Chemical and Drug Induced Liver Injury pathology, Extracellular Matrix metabolism, Extracellular Matrix pathology, Gene Expression Regulation, Genetic Vectors metabolism, Hepatic Stellate Cells metabolism, Hepatic Stellate Cells pathology, Hepatocytes pathology, Humans, Liver Cirrhosis chemically induced, Liver Cirrhosis genetics, Liver Cirrhosis pathology, Mice, MicroRNAs metabolism, Transforming Growth Factor beta antagonists & inhibitors, Transforming Growth Factor beta pharmacology, Chemical and Drug Induced Liver Injury therapy, Dependovirus genetics, Genetic Vectors administration & dosage, Hepatocytes metabolism, Liver Cirrhosis therapy, MicroRNAs genetics
- Abstract
Fibrosis refers to the accumulation of excess extracellular matrix (ECM) components and represents a key feature of many chronic inflammatory diseases. Unfortunately, no currently available treatments specifically target this important pathogenic mechanism. MicroRNAs (miRNAs) are short, non-coding RNAs that post-transcriptionally repress target gene expression and the development of miRNA-based therapeutics is being actively pursued for a diverse array of diseases. Because a single miRNA can target multiple genes, often within the same pathway, variations in the level of individual miRNAs can potently influence disease phenotypes. Members of the miR-29 family, which include miR-29a, miR-29b and miR-29c, are strong inhibitors of ECM synthesis and fibrosis-associated decreases in miR-29 have been reported in multiple organs. We observed downregulation of miR-29a/b/c in fibrotic livers of carbon tetrachloride (CCl4) treated mice as well as in isolated human hepatocytes exposed to the pro-fibrotic cytokine TGF-β. Importantly, we demonstrate that a single systemic injection of a miR-29a expressing adeno-associated virus (AAV) can prevent and even reverse histologic and biochemical evidence of fibrosis despite continued exposure to CCl4. The observed therapeutic benefits were associated with AAV transduction of hepatocytes but not hepatic stellate cells, which are the main ECM producing cells in fibroproliferative liver diseases. Our data therefore demonstrate that delivery of miR-29 to the hepatic parenchyma using a clinically relevant gene delivery platform protects injured livers against fibrosis and, given the consistent fibrosis-associated downregulation of miR-29, suggests AAV-miR-29 based therapies may be effective in treating a variety of fibroproliferative disorders.
- Published
- 2015
- Full Text
- View/download PDF
17. Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation.
- Author
-
Rao S, Ghanta M, Lee IJ, Gillespie A, Parekh HK, Geier SS, Zeng X, Karachristos A, Lau KN, Karhadkar S, Di Carlo A, Sifontis NM, and Constantinescu S
- Subjects
- Adult, Black or African American, Aged, Biomarkers blood, Biopsy, Female, Graft Rejection drug therapy, Graft Rejection ethnology, Graft Rejection immunology, Graft Survival drug effects, Histocompatibility Testing, Humans, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Philadelphia, Predictive Value of Tests, Retrospective Studies, Risk Factors, Survival Analysis, Time Factors, Treatment Outcome, HLA Antigens immunology, Histocompatibility, Isoantibodies blood, Kidney Transplantation adverse effects, Kidney Transplantation mortality, Monitoring, Immunologic
- Abstract
Kidney transplantation (KT) recipients with donor specific HLA antibodies (DSA) encounter higher rates of acute rejection and inferior allograft survival. We report our single center experience with prospective DSA monitoring and provide details of treatments utilized to overcome the potential impact of DSA in a cohort of predominantly African American adult KT recipients. Seventy-five flow crossmatch negative KT recipients underwent periodic screening for DSA utilizing the single antigen bead assay at 3, 6, 9, and 12 months post-transplant. Allograft biopsies were performed in the presence of DSA and/or evidence of graft dysfunction. The incidence of DSA was 23%, with a predominance of Class II antibodies. The rate of rejection was 6 times higher in DSA positive KT recipients compared to DSA negative patients (41% versus 7%, p = 0.004). In the DSA positive group, rejections occurred exclusively in the presence of de novo DSA and were predominantly antibody-mediated or mixed rejections. Despite a higher incidence of rejection in KT recipients with DSA, there were no significant differences in serum creatinine, graft survival, and patient survival between DSA positive and negative recipients at median follow-up of 18 months. DSA positive patients had significantly higher proteinuria compared to DSA negative recipients at 6 months, 1 year, and 3 years of follow-up. In conclusion, the detrimental effects of DSA on allograft function could be mitigated by serial DSA surveillance, protocol biopsies, and alterations in immunosuppression. With these measures, the improvement in graft survival in DSA positive KT recipients, at least at short-term, is encouraging.
- Published
- 2014
18. Balloon dilatation of ureteric strictures.
- Author
-
Punekar SV, Rao SR, Swami G, Soni AB, Kinne JS, and Karhadkar SS
- Subjects
- Adolescent, Adult, Female, Humans, Male, Treatment Outcome, Ureteral Obstruction etiology, Catheterization, Ureteral Obstruction therapy
- Abstract
Aims: Evaluation of dilatation as a minimally invasive technique for the treatment of ureteric strictures., Material and Methods: We evaluated this technique in 16 patients with ureteric and secondary pelviureteric junction strictures from June 1998. Of these, 7 were men and 9 were women. The age range was from 14 to 40 years., Results: Balloon dilatation was successful in 69% of patients. Strictures secondary to previous surgery had nearly 100% success. Of the 8 cases diagnosed as genitourinary tuberculosis, success rate was 50%., Conclusions: Factors affecting success of balloon dilatation are: a) age of the stricture b) length of the stricture and c) etiology of the stricture. In a select group of patients with fresh post-operative or post-inflammatory strictures, balloon dilatation may be an attractive alternative to surgery.
- Published
- 2000
19. Xanthogranulomatous pyelonephritis presenting as emphysematous pyelonephritis: a rare association.
- Author
-
Punekar SV, Kinne JS, Rao SR, Madiwale C, and Karhadkar SS
- Subjects
- Aged, Female, Humans, Pyelonephritis complications, Pyelonephritis, Xanthogranulomatous complications
- Abstract
Xanthogranulomatous and emphysematous pyelonephritis are two rare variants of pyelonephritis. Their combined occurrence is a very rare condition, which has been documented in our case.
- Published
- 1999
20. Martius' labial fat pad interposition and its modification in complex lower urinary fistulae.
- Author
-
Punekar SV, Buch DN, Soni AB, Swami G, Rao SR, Kinne JS, and Karhadkar SS
- Subjects
- Female, Humans, Recurrence, Surgical Flaps, Urethral Diseases surgery, Urinary Fistula surgery, Vesicovaginal Fistula surgery
- Abstract
Objective: To assess the results of Martius' labial fat pad interposition and its modification using skin island in the repair of giant and recurrent vesicovaginal and urethrovaginal fistulae., Patients and Methods: Fifteen patients of urethrovaginal and vesicovaginal fistulae underwent Martius' labial fat pad interposition and its skin island modification during 1996 to 1999. Ten of these were recurrent (66%) and five were giant fistulae (34%) i.e. more than five cms., Results: Results were very gratifying with a successful repair in 14 patients (93%). Two patients had transient, low-grade stress incontinence, which did not need any additional procedure. In one patient, there was failure of repair, which was later successfully repaired using fat pad from opposite labia., Conclusion: Martius' fat pad interposition provides vascularity and surface for epithelialisation and also prevents overlapping of vesical/urethral and vaginal suture lines. Martius' repair has good results with low morbidity in the treatment of giant and recurrent urethrovaginal and vesicovaginal fistulae.
- Published
- 1999
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.